Accelerating Clinical Progress in Fibrosis
We are currently advancing first-in-class antibodies in clinical studies to address fibrosis in several indications including those in lung (IPF) and systemic sclerosis (SSc). Our foundational and robust science supports future expansion opportunities into other indications, which could include hepatic, renal, and cardiac fibrosis.
Our Pipeline
- Target
- Clinical Candidate
- Preclinical
- IND-enabling
- Phase 1
- Phase 2
- Product Rights
WNT1-inducible signaling pathway protein-1 (WISP1) is a secreted matricellular protein shown to have a relevant role in fibrosis progression, making the protein a compelling target for anti-fibrosis therapeutics. MTX-463 is a first-in-class human IgG1 antibody designed to neutralize the WISP1-mediated fibrotic signaling that spans several fibrotic indications, including those in the lung and liver. A Phase 2 study of MTX-463 in patients with Idiopathic Pulmonary Fibrosis (IPF) is now open and more information can be found at: wispertrial.com
Ephrin ligands (like EphrinB2) and Eph receptors mediate biological processes involved in tissue fibrosis including cell migration, myofibroblast activation, and tissue remodeling. A growing body of evidence has implicated EphrinB2 in the fibrosis of the skin, lungs, and heart. MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis. A Phase 1 clinical study was completed in 1H-2025 in Australia (NCT06535841) and a Phase 2 study of MTX-474 in patients with Systemic Sclerosis (SSc) is anticipated to initiate in 2H-2025.
SMOC2 is a secreted matricellular protein that promotes extracellular matrix assembly, cell adhesion and fibrosis. In human studies across fibrotic indications, SMOC2 expression levels correlate with fibrotic disease severity and/or outcomes. Mediar is conducting optimization of lead SMOC2 antibodies with plans to nominate a clinical candidate in 1H-2025. Initial indications of interest include fibrosing diseases of the kidney.